Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced NUT Carcinoma”

11 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 11 results

Testing effectiveness (Phase 2)Looking for participantsNCT05019716
What this trial is testing

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

Who this might be right for
Advanced NUT CarcinomaMetastatic NUT CarcinomaUnresectable NUT Carcinoma
National Cancer Institute (NCI) 36
Early research (Phase 1)Looking for participantsNCT05488548
What this trial is testing

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

Who this might be right for
Castrate Resistant Prostate CancerNUT CarcinomaChronic Myelomonocytic Leukemia+1 more
Epigenetix, Inc. 75
Early research (Phase 1)Study completedNCT02307240
What this trial is testing

Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors

Who this might be right for
Triple-Negative Breast CancerHigh-grade Serous Ovarian CancerSolid Tumors+1 more
Curis, Inc. 43
Not applicableActive Not RecruitingNCT05812027
What this trial is testing

A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

Who this might be right for
Head and Neck CancerCervical CancerNon Small Cell Lung Cancer+4 more
TScan Therapeutics, Inc. 1,150
Early research (Phase 1)Study completedNCT02259114
What this trial is testing

A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)

Who this might be right for
NUT Midline CarcinomaTriple Negative Breast CancerNon-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation+3 more
Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 47
Early research (Phase 1)Study completedNCT02516553
What this trial is testing

BI 894999 First in Human Dose Finding Study in Advanced Malignancies

Who this might be right for
NeoplasmsNUT Carcinoma
Boehringer Ingelheim 174
Testing effectiveness (Phase 2)Ended earlyNCT02711137
What this trial is testing

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Who this might be right for
Solid Tumors
Incyte Corporation 137
Early research (Phase 1)Ended earlyNCT02369029
What this trial is testing

BAY1238097, First in Man

Who this might be right for
Neoplasms
Bayer 8
Testing effectiveness (Phase 2)Looking for participantsNCT06943521
What this trial is testing

MT-4561 in Patients With Various Advanced Solid Tumors

Who this might be right for
Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Esophageal Cancer+13 more
Tanabe Pharma America, Inc. 27
Testing effectiveness (Phase 2)Ended earlyNCT02431260
What this trial is testing

An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies

Who this might be right for
Solid Tumors and Hematologic Malignancy
Incyte Corporation 69
Early research (Phase 1)Ended earlyNCT02698176
What this trial is testing

A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)

Who this might be right for
NUT Midline Carcinoma (NMC)Triple Negative Breast Cancer (TNBC)Non-small Cell Lung Cancer (NSCLC)+1 more
Merck Sharp & Dohme LLC 13